C4 Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 3.3 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 405.98M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutat...